Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
tolterodine
|
| gptkbp:availableFormats |
oral solution
extended-release capsule |
| gptkbp:brand |
gptkb:Detrol
|
| gptkbp:clinicalTrials |
improving quality of life
Long-term use effects symptomatic relief Efficacy in overactive bladder Safety profile |
| gptkbp:contraindication |
gptkb:myasthenia_gravis
urinary retention gastric retention |
| gptkbp:date |
2001-10-24
|
| gptkbp:dosageForm |
1 mg
2 mg |
| gptkbp:drugInterdiction |
anticholinergic
|
| gptkbp:formulation |
tablet
|
| gptkbp:gestationPeriod |
Category C
|
| gptkbp:hasPopulation |
adults
elderly children (not recommended) |
| gptkbp:healthcare |
avoid alcohol
stay hydrated do not drive if dizzy |
| https://www.w3.org/2000/01/rdf-schema#label |
Detrol IR
|
| gptkbp:impact |
as needed
|
| gptkbp:interactsWith |
antihistamines
CYP3A4 inhibitors CYP2D6 inhibitors muscle relaxants |
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketedAs |
gptkb:Detrol_IR
gptkb:Detrol_LA |
| gptkbp:nutritionalValue |
liver
|
| gptkbp:regulatoryCompliance |
prescription only
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
dizziness
constipation dry mouth blurred vision |
| gptkbp:storage |
room temperature
away from moisture away from light |
| gptkbp:usedFor |
overactive bladder
|
| gptkbp:waterManagement |
urine
|